STOCK TITAN

Scholar Rock Holding Corporation - $SRRK STOCK NEWS

Welcome to our dedicated page for Scholar Rock Holding Corporation news (Ticker: $SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scholar Rock Holding Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scholar Rock Holding Corporation's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.28%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.59%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.84%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
44.67%
Tags
Scholar Rock Holding Corporation

Nasdaq:SRRK

SRRK Rankings

SRRK Stock Data

1.22B
48.17M
2.25%
106.94%
16.08%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CAMBRIDGE

About SRRK

scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s